Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 11 June 2019. Bassil Akra.

Executive Summary

TÜV SÜD Product Service's Bassil Akra is concerned that there won't be enough notified bodies to audit to the new EU Medical Device and In Vitro Diagnostic Regulations when they come into force in 2020 and 2022, respectively. Check out his comments here.

"We are hiring like crazy. As a notified body, we have been hiring for the MDR and IVDR for the past three, four years. But it will not be sufficient because we can't find all of these experts. They are not available out there. The market is getting really tough. And this is the point where we expect for IVD to be a big problem because there will not be enough notified bodies. And this is where I believe that IVD is going to be the biggest big bomb that we will see in the next two years." – Bassil Akra, VP, TÜV SÜD Product Service

Click here for a free trial of Medtech Insight

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel